evolution from the board of directors
Paris, September 5, 2022. The Sanofi Board of Directors met on September 2, 2022 and unanimously appointed Frédéric Oudéa as “censor‘ (non-voting member) of the Executive Board with immediate effect.
The appointment of Frédéric Oudéa to the Board of Directors will be submitted to the next Annual General Meeting for approval. Following this shareholders’ meeting, it will be proposed to the Sanofi board of directors to appoint Frédéric Oudéa as non-executive chairman of the board, replacing Serge Weinberg, whose term of office has expired. Frédéric Oudéa has announced that he will step down from his position as CEO and director of Société Générale in May 2023.
Serge Weinberg
Chairman of Sanofi
“That makes me happy Frederic Oudea has agreed to join the Board of Directors ‘censor‘ and, if AGM agrees, to become a director, succeeding me as Chairman of the Board. His experience managing and leading the digital transformation of a large global company in one maximum regulated sector, its understanding of governance Affairs, his financial ability, integrity, rigor and sense of responsibility give me confidence that he will be successful in his future role. frederic Oudea and Paul Hudson, Chief Executive Officer of Sanofi, will form an excellent duo to position and strengthen Sanofi as the modern healthcare company the enterprise as a French, European and global leader at the service of patients.”
frederic Oudea
CEO, Societe Generale
“I am very pleased to join the board of Sanofi as ‘censor‘with a view to presidency if its shareholders authorizeand I would like to thank the Board of Directors and its Chairman Serge Weinberg for their support trust. I’m extremely motivated by the prospect of contribute on the strategy and sustainable development of Sanof in the coming yearsa leVein in a strategic, high-impact healthcare sector undergoing major transformation, and the…
